Media.Player

Suppression of SARS replication by SARS helicase inhibitors

標題

SUPPRESSION OF SARS REPLICATION BY SARS HELICASE INHIBITORS

詳細技術說明

None

*Abstract

Severe acute respiratory syndrome (SARS), a life-threatening form of pneumonia, was identified in 2003 as a new never before seen disease. Currently, no approved therapeutics for the treatment of SARS infection exists. In 2002, SARS emerged from Southern China and spread to other parts of the world including North America, South America and Europe. The World Health Organization estimated that SARS killed ~1,000 people and had a mortality rate of ~15%. Moreover, SARS had an immense impact in the global economy, costing >15 billion dollars and devastating Asian economies. While SARS is currently not a public threat, the possibility of future outbreaks of both SARS and related viruses warrants continuous research for discovery of antiviral therapies.The current invention developed by researchers at the University of Missouri is a novel compound for treatment of SARS and possibly other coronaviruses. This compound works by inhibiting the SARS helicase nsp13. This novel compound inhibits the nucleic acid unwinding activity of nsp13, but it does not interfere with the ATPase enzymatic activity or nucleic acid binding function of nsp13. Preliminary results also show that the compound inhibits Mouse Hepatitis Virus. Given the strong sequence similarities among coronaviruses, this inhibitor has the potential to be a valuable tool for understanding the replication mechanism of coronaviruses in addition to SARS CoV.POTENTIAL AREAS OF APPLICATIONSØ SARS & Coronavirus therapyØ Broad spectrum antiviral against other coronaviruses such as porcine coronavirus, transmissible gastroenteritis coronavirus (TGE), bovine coronavirus, canine coronavirus and Feline Infectious Peritonitis Virus (which can be lethal to cats)MAIN ADVANTAGES OF INVENTIONØ Currently, there are no FDA-approved antiviral against coronavirusesØ Compound is specific to its targetØ Shown to work in cell-based assaysØ Most potent nsp13 inhibitorØ Does not inhibit nucleic acid binding or ATP hydrolysisSTATE OF DEVELOPMENT: Ongoing studies are being conducted.LICENSING POTENTIAL: University seeks licensure with the potential to commercializePATENT STATUS: Patent application anticipatedINVENTORS: Stefan G. Sarafianos and Adeyemi O. AdedejiCONTACT INFORMATION:Harriet F. Francis, MS, JD; francish@missouri.edu; 573-884-0374Nancy Parker, PhD; parkern@missouri.edu; 573-884-3553

*IP Issue Date

Feb 23, 2016

*IP Publication Date

Jan 2, 2014

*Principal Investigation

Name: Stefan Sarafianos, Assistant Professor

Department:

Name: Adeyemi Adedeji, Clinical Pathology Resident

Department:

申請日期

Jun 17, 2013

申請號碼

9,266,844

其他

國家/地區

美國